SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES

    公开(公告)号:EP4209213A1

    公开(公告)日:2023-07-12

    申请号:EP22150358.4

    申请日:2022-01-05

    摘要: The present invention pertains to the treatment of proliferative diseases, such as cancer. In particular, the invention describes a novel combination therapy strategy, comprising a Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, an Inhibitor of κB (IκB) Kinase (IKK)/Nuclear Factor κB (NFκB) - signaling inhibitor, and a B-cell lymphoma 2 (BCL-2) inhibitor for the treatment and/or prevention of proliferative diseases, such as cancer. The invention provides such inhibitory compounds and their combinations for use in medical applications, as well as pharmaceutical compositions comprising the compounds of the invention. The invention further pertains to a method of treatment and/or prevention of a proliferative disease in a subject, the method comprising administering to the subject as single treatments or one or more combinatorial treatments, either sequentially or concomitantly, a therapeutically effective amount of inhibitors of RIPK1, inhibitors of IKK/NFκB - signalling, and inhibitors of BCL-2.

    ANTIBODIES AGAINST INFECTIOUS PATHOGENS AND METHOD FOR PRODUCTION THEREOF

    公开(公告)号:EP3805263A1

    公开(公告)日:2021-04-14

    申请号:EP19201736.6

    申请日:2019-10-07

    发明人: Klein, Florian

    IPC分类号: C07K16/10 C12N5/0781 C12N5/16

    摘要: The present invention relates to a method for obtaining monoclonal human antibodies directed against an infectious pathogen, monoclonal human antibodies or binding fragments thereof which are directed against an infectious pathogen as obtained by the method of the invention, a pharmaceutical composition comprising such monoclonal human antibodies, a kit comprising such antibodies, and the monoclonal antibodies or binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament and in the treatment or prevention of a disease caused by the infectious pathogen.

    A METHOD OF CULTURING HAEMATOCOCCUS SPECIES FOR MANUFACTURING OF ASTAXANTHIN

    公开(公告)号:EP3347484A1

    公开(公告)日:2018-07-18

    申请号:EP16770222.4

    申请日:2016-09-09

    IPC分类号: C12P23/00

    摘要: A method of culturing Haematococcus species for manufacturing of astaxanthin comprising the steps of: - providing a substrate, - arranging the Haematococcus species on the surface of the substrate, - exposing the Haematococcus species arranged on the substrate to high light intensities from the beginning of a culturing process and avoiding a two-step culturing process of the Haematococcus species with a first step which is an initial culturing taking place by exposure of the Haematococcus species to low light energy followed by a second step of subsequent culturing of the Haematococcus species by exposure of the Haematococcus species to higher light energy than applied in the first step to induce astaxanthin formation, and optionally - harvesting the cultured Haematococcus species and/or - isolating astaxanthin.

    INHIBITOREN ZUR HEMMUNG DER TUMORMETASTASIERUNG
    59.
    发明公开
    INHIBITOREN ZUR HEMMUNG DER TUMORMETASTASIERUNG 审中-公开
    INHIBITORENZEN ZUR HEMMUNG DER TUMORMETASTASIERUNG

    公开(公告)号:EP3230300A1

    公开(公告)日:2017-10-18

    申请号:EP15808218.0

    申请日:2015-12-11

    IPC分类号: C07K5/12 A61K31/55 A61P35/00

    CPC分类号: C07K7/06 A61K38/00 C07D519/00

    摘要: The invention relates to chemical compounds that can be used in particular as structural mimetics of proline-rich peptides. The compounds of the invention are capable of selectively inhibiting ena/VASP-EVH1-mediated protein-protein interactions. The invention further relates to the use of said compounds as pharmaceutical active substances and to the use of the pharmaceutical active substances to treat tumor diseases. The chemical compounds of the invention can strongly inhibit the chemotaxis and motility of invasive tumor cells and thus can be used in the treatment and/or prevention of tumor metastases.

    摘要翻译: 本发明涉及可特别用作富含脯氨酸肽的结构模拟物的化学化合物。 本发明的化合物能够选择性地抑制ena / VASP-EVH1介导的蛋白质 - 蛋白质相互作用。 本发明进一步涉及所述化合物作为药物活性物质的用途以及药物活性物质用于治疗肿瘤疾病的用途。 本发明的化学化合物可强烈抑制侵袭性肿瘤细胞的趋化性和运动性,因此可用于治疗和/或预防肿瘤转移。

    SILIZIUMHALTIGE ORGANISCHE SÄUREDERIVATE ALS UMWELTFREUNDLICHE AFFF-LÖSCHMITTEL
    60.
    发明公开
    SILIZIUMHALTIGE ORGANISCHE SÄUREDERIVATE ALS UMWELTFREUNDLICHE AFFF-LÖSCHMITTEL 有权
    SILIZIUMHALTIGE ORGANISCHESÄUREDERIVATEALS UMWELTFREUNDLICHE AFFF-LÖSCHMITTEL

    公开(公告)号:EP3188806A1

    公开(公告)日:2017-07-12

    申请号:EP15766072.1

    申请日:2015-09-02

    IPC分类号: A62D1/02

    摘要: The invention relates to a fire fighting foam concentrate comprising a first surfactant, the first surfactant having an acid group as well as an oligosilane unit and/or oligosiloxane unit. The invention further relates to a method for extinguishing fires, comprising the steps of: providing a fire fighting foam concentrate; adding the fire fighting foam concentrate to water to obtain a mixture and bringing the fire into contact with the mixture; wherein the fire fighting foam concentrate is a fire fighting foam concentrate according to the invention. A further object of the invention is the use of a surfactant as an additive to fire fighting foams and/or fire fighting foam concentrates, the surfactant comprising an acid group as well as an oligosilane unit and/or oligosiloxane unit. An example is the following: (formula)

    摘要翻译: 本发明涉及灭火泡沫浓缩物,其包含第一表面活性剂,第一表面活性剂具有酸基以及低聚硅烷单元和/或低聚硅氧烷单元。 本发明还涉及一种灭火方法,包括以下步骤:提供灭火泡沫浓缩物; 将灭火泡沫浓缩物加入水中以获得混合物并使火与该混合物接触; 其中所述灭火泡沫浓缩物是根据本发明的灭火泡沫浓缩物。 本发明的另一个目的是表面活性剂作为灭火泡沫和/或灭火泡沫浓缩物的添加剂的用途,所述表面活性剂包含酸基团以及低聚硅烷单元和/或低聚硅氧烷单元。 一个例子如下:(公式)